Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma

This research study will evaluate the safety and efficacy of a study drug called Umbralisib (also known as TGR-1202) alone as a possible treatment for Waldenstrom's Macroglobulinemia that has come back or that has not responded to standard treatment.

Additional locations may be listed on ClinicalTrials.gov for NCT03364231.

See trial information on ClinicalTrials.gov for a list of participating sites.

Trial PhasePhase II

Trial Typetreatment

Lead OrganizationTG Therapeutics Inc

• Primary IDTGR-1202-202
• Secondary IDsNCI-2018-00242
• ClinicalTrials.gov IDNCT03364231